Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses.

Elise Landais1, Alexis Morice, Heather M Long

  • 1Institut National de la Santé et de la Recherche Médicale, Unité 601, Institut de Biologie, Nantes, France.

Journal of Immunology (Baltimore, Md. : 1950)
|July 20, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VRC01-CLASS PRECURSOR FREQUENCY IN AN AFRICAN POPULATION IS INFLUENCED BY IGHV1-2 ALLELIC COMPOSITION AND NOT MALARIA EXPOSURE.

Research square·2026
Same author

Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Leukemia·2026
Same author

Beyond the Usual Suspects: Emerging Associations Between Epstein-Barr Virus Infection/Infectious Mononucleosis and Cancers.

Reviews in medical virology·2026
Same author

Structural and immunogenetic signatures guide CD4-mimetic HIV vaccine development.

Cell reports·2026
Same author

Assessing T-cell responses to Epstein-Barr virus in individuals at risk for nasopharyngeal carcinoma.

Infectious agents and cancer·2026
Same author

The T Cell Response to Epstein-Barr Virus.

Current topics in microbiology and immunology·2026

Six Epstein-Barr virus (EBV)-specific CD4 T cell clones cross-reacted with cells expressing common human leukocyte antigen (HLA) class II molecules. These T cells effectively targeted EBV-transformed cells and dendritic cells, suggesting a method for depleting alloreactive T cells.

Area of Science:

  • Immunology
  • Transplantation Immunology
  • Viral Immunology

Background:

  • Alloreactive T cells, particularly CD4 T cells, are central to graft-versus-host disease and allograft rejection.
  • Herpesvirus infections can shape the T cell repertoire, influencing transplant outcomes.

Purpose of the Study:

  • To characterize Epstein-Barr virus (EBV)-specific CD4 T cell clones for cross-reactivity with allogeneic cells.
  • To investigate the potential of these clones for selective T cell depletion in transplantation.

Main Methods:

  • Isolation and characterization of six distinct EBV-specific CD4(+) T cell clones.
  • Assessment of T cell cross-reactivity against EBV-transformed lymphoblastoid cell lines (LCLs), dendritic cells, and endothelial cells expressing common MHC class II alleles.

Related Experiment Videos

  • Evaluation of T cell-mediated cytotoxicity and cytokine production (TNF-alpha).

    • Main Results:

    • Six EBV-specific CD4(+) T cell clones demonstrated cross-reactivity with allogeneic cells expressing specific MHC class II alleles.
    • These T cell clones efficiently killed allogeneic LCLs and dendritic cells but not autologous LCLs.
    • Endothelial cells induced significant TNF-alpha production by the T cell clones, despite poor killing.

    Conclusions:

    • EBV-specific CD4(+) T cells exhibit MHC-restricted alloreactivity.
    • EBV-transformed LCLs are potent targets for alloreactive T cells, supporting their use in selective T cell depletion strategies.
    • These findings have implications for managing T cell responses in transplantation.